User:Mr. Ibrahem/Capmatinib

Capmatinib, sold under the brand name Tabrecta, is a medication used to treat non-small cell lung cancer (NSCLC). Specifically it is used for metastatic disease with MET exon 14 skipping. This is found in 3-4% of people with lung cancer. It is taken by mouth.

Common side effects include peripheral swelling, nausea, tiredness, shortness of breath, and decreased appetite. Other side effects may include pneumonitis, liver problems, and sunburns. Use during pregnancy may harm the baby. It is a tyrosine kinase inhibitor.

Capmatinib was approved for medical use in the United States in 2020. It is not approved in Europe or the United Kingdom as of 2021. In the United States 4 weeks costs about 19,800 USD as of 2021.